<DOC>
	<DOCNO>NCT00508287</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacokinetics pharmacodynamics single dos BMS-686117</brief_summary>
	<brief_title>Study Evaluate Safety , Pharmacokinetics , Pharmacodynamics BMS-686117 Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Diagnosis Type 2 diabetes ≥ 3 month treat metformin , thiazolidinedione , sulfonylurea ( either monotherapy combination ) diet alone ( drug naïve ) Fasting plasma glucose : 126 240 mg/dL Hemoglobin A1c : 6 10 % Estimated CrCl ≥ 60 mL/min ALT ≤ 1.5 x ULN total bilirubin ≤ 2 x ULN Stable well control hypertension and/or dyslipidemia Concomitant medication use hypertension and/or dyslipidemia , thyroid hormone replacement therapy low dose aspirin allow stable least 6 week Women childbearing potential Symptomatic diabetes polyuria and/or polydipsia History diabetic ketoacidosis hyperosmolar nonketotic syndrome History renal disease include diabetic nephropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>